
The Noreen O'Neill Melanoma Research Symposium: Host Response in Melanoma
The past decade has seen tremendous advances in the treatment of melanoma with next generation approaches like targeted therapies, immunotherapies and combination therapies that have changed the disease outcome for many patients. Despite the success of these varied strategies, the onset of drug resistance, or failure to respond to therapies at all remains a problem for the majority of patients. How the host and tumor microenvironment play a role in the success of failure of these therapies is an important area of study.
The Wistar Institute
3601 Spruce Street
Philadelphia, PA 19104
Speakers
University of Pennsylvania
Timothy Chan, M.D., Ph.D.
Memorial Sloan Kettering Cancer Center
Patrick Hwu, M.D.
MD Anderson Cancer Center
Carmit Levy, Ph.D.
Tel Aviv University
Richard Marais, Ph.D.
Cancer Research UK Manchester Institute
Sergio Quezada, Ph.D.
University College London
Suzanne Topalian, M.D.
Johns Hopkins University School of Medicine
Thomas Tüting, M.D.
Otto-von-Guericke Universität Magdeburg
Jennifer Wargo, M.D.
MD Anderson Cancer Center
Ashani T. Weeraratna, Ph.D.
The Wistar Institute
Agenda
This is a preliminary agenda. Please check back for updates closer to the symposium.
8:00 AM |
Registration and Breakfast |
|
9:00 AM |
Welcome |
|
9:15 - 9:45 AM |
“The Microbiome and Response to Melanoma Therapy” |
|
9:45 - 10:15 AM |
“Immunotherapy: Evolving Landscape of Mechanisms and Biomarkers” |
|
10:15 - 10:30 AM |
Break |
|
10:30 - 11:00 AM |
“UV Exposure, Adipocytes and Melanoma” |
|
11:00 - 11:30 AM |
“New Insights into Copper-Modulated MAPK Signaling Essential for BRAFV600E Tumorigenesis” |
|
11:30 AM - 12:00 PM |
“A Wrinkle in TiME- How the Aging TME Drives Melanoma Progression” |
|
12:00 PM |
Lunch |
|
1:15 - 1:45 PM |
“From Basic Biology to Therapeutic Opportunities in Melanoma” |
|
1:45 - 2:15 PM |
“Adaptive Plasticity of Tumor and Immune Cells in the Melanoma Microenvironment” |
|
2:15 - 2:30 PM |
Break |
|
2:30 - 3:00 PM |
“Intrinsic Tumor Genomic and Metabolic Factors Leading to Immunoresistance” |
|
3:00 - 3:30 PM |
“PD-1 Blockade in Melanoma and Other Skin Cancers” |
|
3:30 - 4:00 PM |
“Targeting Regulatory T cells for Therapeutic Gain: Means and Mechanisms” |
|
4:00 - 4:15 PM |
Closing Remarks |
|
4:30 - 6:00 PM |
Reception and Poster Session |